Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?

Clin Gastroenterol Hepatol. 2014 Jun;12(6):1051-4.e1. doi: 10.1016/j.cgh.2013.10.034. Epub 2013 Nov 7.

Abstract

Authors have reported conflicting results on the persistence of hepatitis C virus (HCV) infection in patients having sustained virologic response (SVR) to treatment. Therefore, we sought to determine whether chemotherapy leads to viral relapse in 30 HCV-infected patients who had SVR before cancer diagnosis. Half of them had hematologic malignancies. Most (60%) received HCV therapy with interferon and ribavirin. Chemotherapy was started at a median of 72 months after SVR and included rituximab (27%), cyclophosphamide (23%), cisplatin (17%), or corticosteroids (37%). No patient had post-SVR viral relapse. Therapeutically induced resolution of HCV appears to be permanent and not affected by chemotherapy.

Keywords: Chemotherapy; Hepatitis C Virus; Interferon; Ribavirin; SVR.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use*
  • Antiviral Agents / therapeutic use
  • Female
  • Hepacivirus / isolation & purification*
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / epidemiology*
  • Humans
  • Incidence
  • Interferon-alpha / therapeutic use
  • Liver Neoplasms / complications*
  • Liver Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Ribavirin / therapeutic use

Substances

  • Antineoplastic Agents
  • Antiviral Agents
  • Interferon-alpha
  • Ribavirin